DOCSLIB.ORG

Pharmacoutilization of Epoetins in Naïve Patients with Hematological

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacoutilization of Epoetins in Naïve Patients with Hematological Journal name: Biologics: Targets and Therapy Article Designation: ORIGinal RESEARCH Year: 2016 Volume: 10 Biologics: Targets and Therapy Dovepress Running head verso: Perrone et al Running head recto: Pharmacoutilization of epoetins in naïve patients open access to scientific and medical research DOI: http://dx.doi.org/10.2147/BTT.S114625 Open Access Full Text Article ORIGINAL RESEARCH Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars Valentina Perrone1 Aim: The purpose of this study was to assess the prescription of epoetins and consumption Stefania Saragoni1 of health care resources (in terms of drug treatments) in naïve patients with hematological Stefano Buda1 malignancies in a real-world setting; in particular, we compared the results between reference Alessandro Broccoli2 product and biosimilar products. Luca Degli Esposti1 Methods: An observational retrospective study based on administrative and laboratory databases For personal use only. of three local health units was conducted. All adults diagnosed with hematological malignancies 1 CliCon S.r.l., Health, Economics and who had received at least one epoetin (either reference product or biosimilars) prescription & Outcomes Research, Ravenna, 2Institute of Hematology “L. e A. for the first time between 1 January 2010 and 30 April 2012 (enrollment period) were included. Seràgnoli”, University of Bologna, The date of the first prescription of epoetin within the enrollment period was defined as index Bologna, Italy date (ID). Patients were followed up for 4 weeks after ID (follow-up period) and were inves- tigated for the 1-year period before the ID. The difference between the last hemoglobin (Hb) measurement after ID and the one prior to ID (ΔHb) was evaluated. The drug cost analysis was conducted from the perspective of the Italian National Health System. Results: Overall, 69 patients were included in the study; 48 of them received reference epoetin product and 21 received biosimilars as first prescription. Among reference product users, the mean ± standard deviation (SD) age was 62.5±14.7 years; this cohort of patients was slightly Biologics: Targets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 10-Dec-2018 significantly younger than the biosimilar users (71.8±11.8 years). The mean ± SD overall Hb level prior to treatment was lower among patients who started with biosimilar products (9.6±1.1 g/dL) compared to those who started with a reference product (10.1±2.1 g/dL). No significant differences in ΔHb were observed between biosimilar and originator groups during the follow- up period. The mean ± SD cost per patient was €667.98±573.93 and €340.85±235.73 for the reference product and biosimilar users, respectively (p=0.065). Conclusion: Our study showed that the use of biosimilar products might contribute to control- ling health care costs (in terms of drug treatments) for patients with hematological malignancies being maintained by high-quality anemia therapy. Our findings also showed some discordances regarding the most appropriate therapeutic approach in daily clinical practice. Keywords: erythropoiesis-stimulating agents, chemotherapy-induced anemia, biosimilar, Correspondence: Luca Degli Esposti real-world setting CliCon S.r.l., Health, Economics and Outcomes Research, Via Salara, 36, 48100 Ravenna, Italy Introduction Tel +39 544 38393 Anemia is a condition in which the red blood cell mass is insufficient to adequately deliver Fax +39 544 212699 Email [email protected] oxygen to peripheral tissues. Patients with anemia related to cancer, chronic inflammation, submit your manuscript | www.dovepress.com Biologics: Targets and Therapy 2016:10 157–165 157 Dovepress © 2016 Perrone et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work http://dx.doi.org/10.2147/BTT.S114625 you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Powered by TCPDF (www.tcpdf.org) 1 / 1 Perrone et al Dovepress or chronic kidney disease (CKD) generally display a reduced in particular, we compared the results between reference response of endogenous erythropoietin (EPO) to trigger levels product and biosimilar products. of hemoglobin (Hb); this aspect is worsened in those who are concomitantly receiving myelotoxic chemotherapy.1,2 Anemia Methods may significantly impair quality of life, increase cardiovascular Data sources risk, and reduce long-term survival, when left untreated.3 The study was conducted using administrative databases Earlier, treatment options were essentially limited to of three Italian local health units (LHUs), geographically blood transfusions. The introduction of recombinant human distributed throughout the national territory, representing EPO and an erythropoietic stimulating agent (ESA) in 1989 ~550,000 health-assisted individuals. resulted in a major progress in the treatment of anemia and In particular, the following databases were used to retrieve provided a key tool for managing this condition in patients the information: Beneficiaries, Hospital Direct Drugs Distri- with CKD or cancer.4–7 bution Registry, Territorial Pharmacy, Hospital Discharges, In December 2004, the patent of epoetin-alpha (i.e. Ambulatory Care Specialist, Laboratory Analysis (which Eprex®, reference product or originator [Janssen-Cilag, records the date and result of the Hb measurements), and the Neuss, Germany]) expired and this opened the way to Mortalities, where only death dates are reported. biosimilars. Currently, in Europe three biosimilar products The diagnosis and procedures were retrieved using codes have received marketing authorization from the European classified according to the International Classification of Dis- Medicines Agency (EMA): Binocrit® [Sandoz GmbH, eases, Ninth Revision, Clinical Modification (ICD-9-CM). Holzkirchen, Germany] (epoetin-alpha; also known as The information on drug prescriptions was identified through Abseamed® [Medice Arzneimittel Putter GmbH & Co., the International Anatomical Therapeutic Chemical classifi- Iserlohn, Germany] and Epoetin Alfa Hexal® [Hexal Biotech cation system (ATC code). Forschungs GmbH, Holzkirchen, Germany]), Retacrit® To guarantee patient privacy, each subject was assigned an [Hospira, Maidenhead, United Kingdom] (epoetin-zeta; also anonymous univocal numeric code. No identifiers related to For personal use only. called Silapo® [Stada R&D AG, Bad Vilbel, ­Germany]), patients were provided to the researchers. The patient code in and Eporatio® [Ratiopharm GmbH, Ulm, Germany] each database permitted electronic linkage between all data- ( epoetin- theta; also known as Biopoin® [Teva GmbH, Ulm, bases. Informed consent is not required by the LHU ethics Germany]).8 Since 2007, biosimilars of ESAs are available committees for using encrypted retrospective information. on the Italian market.9,10 According to the EMA guidelines, In compliance with the AIFA Determination20 Guidelines a biosimilar is defined as a biological medicinal product for classification and conduction of observational studies on that is developed to be similar to an existing biological (the drugs and AIFA Circular Procedures for launch of observa- “reference medicine”). A biosimilar demonstrates similar- tional studies on drugs, this study was notified to the local ity to the reference medicinal product in terms of quality ethics committee in each participating LHU according to the characteristics, biological activity, safety and efficacy based Italian law regarding the conduct of observational analysis Biologics: Targets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 10-Dec-2018 on a comprehensive comparability exercise.11 and the LHU ethics committees approved the study. Although a biosimilar is approved based on its therapeutic equivalence, the interchangeability is still an open question Cohort definition mark;12 nevertheless, in accordance with the recent European This study was an observational retrospective cohort analysis. directives and the last position paper from the Italian Medicines All naïve patients aged ≥18 years who received at least one Agency (AIFA—Agenzia Italiana del Farmaco), biosimilar dispensing of epoetin (biosimilars [epoetin-alpha biosimilars: epoetins may be prescribed to naïve patients;13,14 however, the Binocrit and Abseamed; epoetin-zeta biosimilar: Retacrit] choice to treat a patient with a biological reference product or or their corresponding reference medical product: Eprex biosimilars is a clinical decision entrusted to the physician.13 [ATC code: B03XA01]) during the enrollment period (from Few real-life data and comparative analysis are available 1 January 2010 to 30 April 2012) were considered eligible concerning the use of originator epoetins and biosimilar candidates for analysis and were enrolled. All these ESAs products in the Italian setting.15–19 The objective of the present have been
Load more

Recommended publications
  • Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
    International Journal of Molecular Sciences Review Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level? Rola El Sayed 1 , Yolla Haibe 2, Ghid Amhaz 2, Youssef Bouferraa 2 and Ali Shamseddine 2,* 1 Global Health Institute, American University of Beirut, Beirut 11-0236, Lebanon; [email protected] 2 Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut 11-0236, Lebanon; [email protected] (Y.H.); [email protected] (G.A.); [email protected] (Y.B.) * Correspondence: [email protected]; Tel.: +961-1-350-000 (ext. 5390) Abstract: Immunotherapy has changed the treatment paradigm in multiple solid and hematologic malignancies. However, response remains limited in a significant number of cases, with tumors de- veloping innate or acquired resistance to checkpoint inhibition. Certain “hot” or “immune-sensitive” tumors become “cold” or “immune-resistant”, with resultant tumor growth and disease progres- sion. Multiple factors are at play both at the cellular and host levels. The tumor microenvironment (TME) contributes the most to immune-resistance, with nutrient deficiency, hypoxia, acidity and different secreted inflammatory markers, all contributing to modulation of immune-metabolism and reprogramming of immune cells towards pro- or anti-inflammatory phenotypes. Both the tumor and surrounding immune cells require high amounts of glucose, amino acids and fatty acids to fulfill their energy demands. Thus, both compete over one pool of nutrients that falls short on needs, obliging cells to resort to alternative adaptive metabolic mechanisms that take part in shaping their inflammatory phenotypes. Aerobic or anaerobic glycolysis, oxidative phosphorylation, tryptophan catabolism, glutaminolysis, fatty acid synthesis or fatty acid oxidation, etc.
    [Show full text]
  • Modulating the Immune System Through Nanotechnology
    Modulating the immune system through nanotechnology Tamara G. Dacobaa,b*, Ana Oliveraa,b*, Dolores Torresb, José Crecente- Campoa,b#, María José Alonsoa,b## aCenter for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain. bDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain. *These authors contributed equally to this work. #Corresponding author e-mail address: [email protected] ##Corresponding author e-mail address: [email protected] 1 Abstract Nowadays, nanotechnology-based modulation of the immune system is presented as a cutting-edge strategy, which may lead to significant improvements in the treatment of severe diseases. In particular, efforts have been focused on the development of nanotechnology- based vaccines, which could be used for immunization or generation of tolerance. In this review, we highlight how different immune responses can be elicited by tuning nanosystems properties. In addition, we discuss specific formulation approaches designed for the development of anti-infectious and anti-autoimmune vaccines, as well as those intended to prevent the formation of antibodies against biologicals. Graphical abstract Keywords: nanotechnology; immune system; tolerance; stimulation; autoimmune disease; vaccine Highlights - Nanocarriers can be designed to target specific immune cells - Nanovaccines may help fighting diseases that are elusive to traditional vaccines - Nanocarriers can bias the immune response from humoral to cellular - Autoimmune disease treatments can be improved with nanotechnology-based approaches - The use of nanocarriers may help to avoid ADAs formation against biotherapeutics 2 1. Introduction The modulation of the immune system is the base of new and promising therapies for some of the most prevalent and/or severe diseases of our time, such as cancer, HIV, and diabetes.
    [Show full text]
  • An Active Immunotherapy Combined with First-Line Weekly Paclitaxel In
    An active immunotherapy combined with first-line weekly paclitaxel in metastatic breast cancer: first results of IMP321 (LAG-3Ig) as an antigen presenting cell activator in the AIPAC phase IIb trial Frédéric Triebel, CSO/CMO Precision: Breast Cancer March 7-8, 2017 Boston, MA. 1 ASX:PRR; NASDAQ:PBMD Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company’s filings to the ASX and SEC for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.
    [Show full text]
  • Molecular Advances in Pediatric Low-Grade Gliomas As a Model
    Published OnlineFirst July 23, 2013; DOI: 10.1158/1078-0432.CCR-13-0662 Clinical Cancer CCR New Strategies Research New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model Eric Raabe1, Mark W. Kieran2, and Kenneth J. Cohen1 Abstract Pediatric low-grade gliomas (pLGG) account for more brain tumors in children than any other histologic subtype. While surgery, chemotherapy and radiation remain the mainstay of upfront treatment, recent advances in molecular interrogation of pLGG have shown a small number of recurring genetic mutations in these tumors that might be exploited therapeutically. Notable findings include abnormalities in the RAS/ MAP kinase pathway such as NF-1 loss or BRAF activation and mTOR activation. Recent identification of activating re-arrangements in c-MYB and MYBL1 in pediatric diffuse astrocytoma also provide candidates for therapeutic intervention. Targeting these molecularly identified pathways may allow for improved outcomes for patients as pediatric oncology moves into the era of biology-driven medicine. Clin Cancer Res; 19(17); 4553–8. Ó2013 AACR. Disclosure of Potential Conflicts of Interest M.W. Kieran is a consultant/advisory board member of Boehringer-Ingelheim, Incyte, Merck, Novartis, and Sanofi. No potential conflicts of interest were disclosed by the other authors. CME Staff Planners' Disclosures The members of the planning committee have no real or apparent conflict of interest to disclose. Learning Objective(s) Upon completion of this activity, the participant should have a better understanding of the molecular pathways that are active in pediatric low-grade gliomas and the biologic rationale underlying novel therapeutic strategies for children with these tumors.
    [Show full text]
  • Anti-Depressant-Like Effect of Curculigoside Isolated from Curculigo Orchioides Gaertn Root
    Wang et al Tropical Journal of Pharmaceutical Research October 2016; 15 (10): 2165-2172 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v15i10.15 Original Research Article Anti-depressant-like effect of curculigoside isolated from Curculigo orchioides Gaertn root Jing Wang1*, Xiao-Li Zhao2 and Lan Gao3 1Neurology Department, Shanxi Provincial People’s Hospital, Taiyuan 030012, 2Neurology Department, The First Hospital of Xi’an City, Xi’an 710002, Shanxi, 3Beijing Huilongguan Hospital, Beijing 100096, China *For correspondence: Email: [email protected]; Tel/Fax: +86-0351-4960171 Received: 5 March 2016 Revised accepted: 9 September 2016 Abstract Purpose: To investigate the anti-depressant-like activity of curculigoside from Curculigo orchioides Gaertn and its underlying mechanism(s). Methods: Antidepressant-like activity was determined in mice through forced swimming test (FST), tail suspending test (TST), and open field test (OFT). Mechanism of action was investigated by measuring levels of dopamine (DA), norepinephrine (NE), and 5-hydroxytryptamine (5-HT) in chronic mild stress (CMS) rats using high-performance liquid chromatography-electron capture detector (HPLC-ECD). Western blotting was used to investigate the effect of curculigoside on the expression of brain-derived neurotrophic factor (BDNF) protein in rats. Results: In FST and TST, treatment of mice with curculigoside (10, 20, 40 mg/kg, p.o.) significantly reduced immobility time, which was, however, unaffected by locomotor activity when assessed in the OFT. The treatment led to significant increases in DA, NE and 5-HT, and up-regulation of BDNF protein expression in the hippocampus of the CMS rats.
    [Show full text]
  • Immunosuppressant Ingredients, Immunostimulant Ingredients
    Immunosuppressant Ingredients, Immunostimulant Ingredients Immunosuppressant Ingredients Immunosuppressant ingredients are chemical and medicinal agents used for the suppression and regulation of immune responses. Pharmacologically speaking, these agents have varied mecha- nisms of action, such as regulation of inflammatory gene expression, suppression of lymphocyte signal transduction, neutralization of cytokine activity, and inhibition lymphocyte proliferation by agent-induced cytotoxicity. Common agents include glucocorticoids, alkylating agents, metabolic antagonists, calcineurin inhibitors, T-cell suppressive agents, and cytokine inhibitors. 5-Aminosalicylic Acid 25g / 500g [A0317] 5-Aminosalicylic acid (5-ASA) is commonly used as a gastrointestinal anti-inflammatory agent. It has in vitro and in vivo pharmacologic effects that decrease leukotriene production, scavenge for free radicals, and inhibits leukocyte chemotaxis et al. Azathioprine 5g / 25g [A2069] Azathioprine is a prodrug of 6-mercaptopurine (6-MP), which inhibits the synthesis of purine ribonucleotides and DNA/RNA. Cyclophosphamide Monohydrate 5g / 25g [C2236] Cyclophosphamide is an antitumor alkylating reagent involved in the cross-linking of tumor cell DNA. Cyclosporin A 100mg / 1g [C2408] Cyclosporin A is a cyclic polypeptide immunosuppressant. It inhibits the activity of T-lymphocytes, and the phosphatase activity of calcineurin. Dimethyl Fumarate 25g / 500g [F0069] Dimethyl fumarate has neuroprotective and immunomodulating effects. Fingolimod Hydrochloride 200mg / 1g [F1018] Fingolimod (FTY720) is an immunomodulatory agent. It is an agonist at sphingosine 1-phosphate (S1P) receptors, and inhibits lymphocyte emigra- tion from lymphoid organs. Iguratimod 25mg / 250mg [I0945] Iguratimod (T-614) is an agent with anti-inflammatory and immunomodulatory activities. Its activity functions by the inhibiting production of immune globulin and inflammatory cytokines such as TNF-α, IL-1β and IL-6, and used as a disease modifying anti-rheumatic drug (DMARD).
    [Show full text]
  • Feline Infectious Peritonitis Treatment
    Addie: Feline infectious peritonitis treatment www.catvirus.com Feline infectious peritonitis (FIP) treatment Diane D. Addie PhD, BVMS, MRCVS www.catvirus.com 22 Feb 2018 IMPORTANT NOTICE Prior to even considering treatment for feline infectious peritonitis (FIP) you absolutely MUST ensure that the cat really does have FIP. At time of writing, FIP treatment is mainly immunosuppressive and immunosuppression of a cat with an infection other than FIP will kill the cat. Do a FCoV antibody test: provided the test is sensitive enough, a negative result will rule out FIP. Addie et al, 2015 You can find out which FCoV antibody tests are recommended (and which ones are useless) at www.catvirus.com/FCoVantibody.htm. A major differential of FIP is toxoplasmosis: run a toxoplasma antibody test in at-risk cats, for example those with access to outdoors or who are fed butcher meat. However a positive FCoV antibody test does NOT confirm FIP. PREVENTION IS BETTER THAN CURE It is my hope that by the time you have listened to this webinar you will have understood the complexity of the disease that is FIP. In many other diseases, the destruction of the invading pathogen, by antivirals or antibiotics, results in the cure of the patient, but FIP is a disease involving the very complex immune response of the cat. If we don’t completely understand the pathogenesis of FIP how can we hope to fix it? And the disease isn’t a fixed target, it changes, the pathology changes throughout the infection. FIP is slightly different in every individual so treatment needs to be tailored to that individual patient: it is not a case of one size fits all.
    [Show full text]
  • Molecular Advances in Pediatric Low-Grade Gliomas As a Model Eric Raabe1, Mark W. Kieran
    Author Manuscript Published OnlineFirst on July 23, 2013; DOI: 10.1158/1078-0432.CCR-13-0662 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model Eric Raabe1, Mark W. Kieran2 and Kenneth J. Cohen1, 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland and 2Dana- Farber/Children’s Hospital Cancer Center, Boston, Massachusetts Corresponding Author: Kenneth J. Cohen, MD, MBA Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1800 Orleans St. Bloomberg 11379 Baltimore, MD 21287 Phone: 1-410-614-5055 Fax: 1-410-955-0028 E-mail: [email protected] Running Title: Molecular Advances in Pediatric LGG Conflict of Interest: Dr. Kieran is an advisor for Boehringer-Ingelheim, Incyte, Merck, Novartis and Sanofi. Funding or Grants: St. Baldrick’s Scholar (ER); Pediatric Low-Grade Astrocytoma Foundation (ER; MWK), Andrysiak Low-Grade Glioma Scholar Award (MWK), Solving Kid’s Cancer (KJC). 1 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2013 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 23, 2013; DOI: 10.1158/1078-0432.CCR-13-0662 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ABSTRACT Pediatric low-grade gliomas (pLGG) account for more brain tumors in children than any other histologic subtype. While surgery, chemotherapy and radiation remain the mainstay of upfront treatment, recent advances in molecular interrogation of pLGG have demonstrated a small number of recurring genetic mutations in these tumors that might be exploited therapeutically.
    [Show full text]
  • A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
    Review A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma Eun-mi Yu 1 , Laura Linville 2, Matthew Rosenthal 2 and Jeanny B. Aragon-Ching 1,* 1 GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA; [email protected] 2 Department of Internal Medicine, George Washington University Medical Center, Washington, DC 20037, USA; [email protected] (L.L.); [email protected] (M.R.) * Correspondence: [email protected]; Tel.: +1-703-970-6431; Fax: +1-703-970-6429 Abstract: The use of checkpoint inhibitors in advanced and metastatic renal cell carcinomas (RCCs) has rapidly evolved over the past several years. While immune-oncology (IO) drug therapy has been successful at resulting in improved responses and survival, combination therapies with im- mune checkpoint inhibitors and vascular endothelial growth factor (VEGF) inhibitors have further improved outcomes. This article reviews the landmark trials that have led to the approval of IO therapies, including the Checkmate 214 trial and combination IO/VEGF TKI therapies with Check- mate 9ER, CLEAR, and Keynote-426, and it includes a discussion on promising therapies moving in the future. Keywords: renal cell cancer; checkpoint inhibitors; immunotherapy; vascular endothelial growth factors Citation: Yu, E.-m.; Linville, L.; Rosenthal, M.; Aragon-Ching, J.B. 1. Introduction A Contemporary Review of Immune Cancers of the kidney and renal pelvis are the sixth most common cancers among Checkpoint Inhibitors in Advanced men and the ninth most common cancers in women. There will be an estimated number of Clear Cell Renal Cell Carcinoma.
    [Show full text]
  • Indications Antidepressant, Mental Stimulant, Psychophysical Antiastenic and Fast Energizing
    Type: antidepressant, tonic-stimulating 6 Indications antidepressant, mental stimulant, psychophysical antiastenic and fast energizing. Recommended daily intake: 30 drops, 3 times a day Physiological value: It is used to contrast physical and mental tiredness Method of preservation: Store in a cool place, protected from light. Contains: 50 ml In the same family: Alato 1 - Dry extract Antidepressant, tonic Complete and in-depth information on www.lafenicesas.it HERBS PRESENT IN THE PRODUCT GINSENG It is an Adaptogenic plant that increases the electrical activity of the cells of the cerebral cortex. It stimulates the cholinergic system. It increases physical endurance and recovery capacity after sports activity. Ginseng enhances memory and resistance to negative environmental factors. Overall, it reduces stress and neurosis, improves adaptation to the stimuli of daily life, enhances physical and mental performance and strengthens the immune system. GUARANA Guarana is rich in caeine and has stimulating and anti-asthenic eect. In the Amazonian ethnomedicine Guarana is the elixir of long life that has tonic, stimulating, anti-fatigue, anti-depressive, astringent, febrifugal, cardiac tonic and diuretic properties. It is also used as cure for headaches, menstrual pains and rheumatism. KOLA NUT Kola nut is rich in caeine and it is an eective nerve tonic. It has tonic, exciting and restorative properties; it helps to decrease the perception of fatigue and breathlessness and improves cardiac contractility, nerve and brain eciency. ELEUTHEROCOCCUS Eleutherococcus is an adaptogen, indicated in states of stress and over-exertion, asthenia, convalescence, psychophysical exhaustion, fatigue and hypotension. It also helps concentration and attention and stimulates the metabolism. It acts on the adrenal glands, increasing the production of 6 adrenal hormones.
    [Show full text]
  • COVID-19: Review of a 21St Century Pandemic from Etiology to Neuro-Psychiatric Implications
    Journal of Alzheimer’s Disease 77 (2020) 459–504 459 DOI 10.3233/JAD-200831 IOS Press Review COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications Vicky Yamamotoa,b,c,d,1, Joe F. Bolanosa,b,1, John Fiallosa,b, Susanne E. Stranda,b, Kevin Morrisa,b, Sanam Shahrokhiniae, Tim R. Cushingf , Lawrence Hoppg, Ambooj Tiwaria,h, Robert Hariria,i,j, Rick Sokolovk, Christopher Wheelera,b,l, Ajeet Kaushikm, Ashraf Elsayeghn, Dawn Eliashiva,o, Rebecca Hedrickp, Behrouz Jafariq, J. Patrick Johnsonr,s, Mehran Khorsandit, Nestor Gonzalezs, Guita Balakhaniu, Shouri Lahiriv, Kazem Ghavidelw, Marco Amayaa,b, Harry Kloora, Namath Hussaina,x, Edmund Huangu, Jason Cormiera,y, J. Wesson Ashforda,z, Jeffrey C. Wanga,aa, Shadi Yaghobianbb, Payman Khorramicc, Bahman Shamloodd, Charles Moonff , Payam Shadibb and Babak Kateba,b,x,ee,gg,∗ aSociety for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA bBrain Mapping Foundation (BMF), Los Angeles, CA, USA cUSC Keck School of Medicine, The USC Caruso Department of Otolaryngology-Head and Neck Surgery, Los Angeles, CA, USA dUSC-Norris Comprehensive Cancer Center, Los Angeles, CA, USA eCedars-Sinai Medical Center, Department of Nutrition, Los Angeles, CA, USA f UCLA-Cedar-Sinai California Rehabilitation Institute, Los Angeles, CA, USA gCedars Sinai Medical Center Department of Ophthalmology and UCLA Jules Stein Eye Institute, Los Angeles, CA, USA hNew York University, Department of Neurology, New York, NY, USA iCelularity Corporation, Warren, NJ, USA jWeill Cornell School
    [Show full text]
  • An Overview of Immunology - Systemic Review
    Original Article An Overview of Immunology - Systemic Review P. Parveen1, P.Usha1, Ch.Sowjanya1, S.V.R.L.Sravika1, Bhavana Ragala1, and M. Gayatri Ramya2* 1Hindu College of Pharmacy Amaravathi Road, Guntur-522002 India. 2Acharya Nagarjuna University, University college of Pharmaceutical Sciences, Nagarjuna Nagar, Guntur-522510 India. ABSTRACT Immunology is one of the most rapidly developing areas of medical biotechnology research and has great promises with regard to the prevention and treatment of a wide range of disorders such as the inflammatory diseases. In addition, infectious diseases are now primarily considered immunological disorders, while neoplastic diseases and organ transplantation and several autoimmune diseases are involved in an immunosuppressive state. Immunomodulators are natural or synthetic substances that help regulate or normalize the Address for immune system. Immunomodulators correct immune systems that are Correspondence out of balance. The benefits of immunomodulators stem from their ability to stimulate natural and adaptive defense mechanisms.A Acharya Nagarjuna number of disorders such as immunodeficiency state, autoimmune University, University disease, cancer and viral infection can be treated with College of immunostimulants drugs. The immune system is a part of body to Pharmaceutical detect the pathogen by using a specific receptor to produce Sciences, Nagarjuna immediately response by the activation of immune components cells, Nagar, Guntur-522510 cytokines, chemokines and also release of inflammatory mediator. India. They modulate and potentiate the immune system. E-mail: rajuph111 @gmail.com Keywords: Immunomodulators, Immunosuppressive, Immunology. INTRODUCTION The immune system is designed to processing of the antigen by the phagocytic protect the host from invading pathogens cells such as macrophages, monocytes, or and to eliminate disease.
    [Show full text]